Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014', provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 6 Therapeutics Development 7 Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview 7 Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis 8 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 9 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 10 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 13 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 14 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 15 Galapagos NV 15 Arsanis Biosciences GmbH 16 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Molecule Type 22 Drug Profiles 24 RUT-5860 - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GLPG-1492 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 acALY-18 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ASN-100 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 siderocillin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LTA-001 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 32 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 34 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 35 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 36 Featured News & Press Releases 36 Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 36 Jan 07, 2013: New compound overcomes drug-resistant Staph infection in mice 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2014 7 Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H2 2014 15 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Arsanis Biosciences GmbH, H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Molecule Type, H2 2014 23 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H2 2014 32 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H2 2014 34 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products, H2 2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.